K. Reckamp - Cedars Sinai Med Ctr | 人才画像

基本信息

浏览量：229

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 435 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Ivonescimab in Advanced NSCLC: is Progression-Free Survival Enough, or Are Overall Survival Data Also Needed

Kamya Sankar,Karen L Reckamp

Lancet (London, England)no. 10481 (2025): 757-759

引用0浏览0WOS引用

CD105 Blockade Restores Osimertinib Sensitivity in Drug-Resistant EGFR-mutant Non-Small Cell Lung Cancer

Manish Thiruvalluvan,Sandrine Billet, Zhenqiu Liu,Joseph Lownik,Barliz Waissengrin, Hyoyoung Kim, Anton L Villamejor, Larry Milshteyn, Xiamo Li,Matthew Gayhart, Manuel Araña,Kamya Sankar,Edwin M Posadas,Jean Lopategui,Sungyong You,Karen L Reckamp,Neil A Bhowmick

Drug resistance updates reviews and commentaries in antimicrobial and anticancer chemotherapy（2025）

引用0浏览0WOS引用

In the Time of COVID-19: Challenges, Successes and Lessons Learned from Studies in Cancer Patients

Philip C Mack,James M Crawford,Andres Chang, Anna Yin,Sabra L Klein,Patrick Shea,Fred R Hirsch, David Zidar,Viviana Simon,Charles Gleason, Russell McBride, Carlos Cordon-Cardo,Jennifer VanOudenhove,Stephanie Halene, F Eun-Hyung Lee, Nicholas Mantis,Lawrence H Kushi,Daniela Weiskopf,Akil Merchant,Karen L Reckamp,Jacek Skarbinski,Jane C Figueiredo

Journal of the National Cancer Institute (2025)

引用0浏览0WOS引用

DNA Damage Repair Gene Alterations Influence the Tumor Immune Microenvironment in Advanced Non-Small Cell Lung Cancer

Kamya Sankar,Jacob Mercer,Ellen B. Jaeger,Jen Godden, Edward Williams, Michael A. Thompson, Shetal A. Patel,Jane C. Figueiredo,Frank Weinberg,Karen L. Reckamp

Lung Cancer (2025): 108444

引用0浏览0WOS引用

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors

Nathaniel J. Myall,Jennifer G. Whisenant,Joel W. Neal,Wade T. Iams,Karen L. Reckamp,Sally York,Lynne D. Berry,Yu Shyr,Leora Horn,Heather A. Wakelee,Sukhmani K. Padda

JTO CLINICAL AND RESEARCH REPORTS（2025）

引用0浏览0WOS引用

Comparison of Tumor Immune Microenvironments Between Primary and Metastatic Sites in Non-Small Cell Lung Cancer

K. Sankar, J. Mercer, E. Jaeger, J. Godden, E. Williams, M. Thompson, S. Patel,K. Reckamp,F. Weinberg

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S457-S457

引用0浏览0引用

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients with SLFN11 Positive Extensive-Stage SCLC: S1929

Nagla Abdel Karim,Jieling Miao,Karen L Reckamp,Carl M Gay,Lauren A Byers, Ying-Qi Zhao,Mary W Redman,Daniel R Carrizosa,Wei-Lien Wang,William J Petty,Kathan Mehta,Bryan A Faller, Edem S Agamah,Samer S Kasbari, Rajini K Malisetti, Atul Kumar,John Schallenkamp, Krishna C Alluri,Jhanelle E Gray,Karen Kelly

Journal of thoracic oncology official publication of the International Association for the Study of Lung Cancerno. 3 (2024): 383-394

引用0浏览0WOS引用

Lung-MAP S1800D: A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Anti-Pd-1 or Anti-Pd-l1 Therapy

John M. Wrangle,Mary Weber Redman, Hatim Husain,Karen L. Reckamp,Tom Stinchcombe,Martin Joseph Edelman,Ticiana Leal,Bryan A. Faller,Katherine Minichiello,Hossein Borghaei,Karen Kelly,Roy S. Herbst,Jhanelle E. Gray

Journal of Clinical Oncologyno. 16_suppl (2024): 2619-2619

引用0浏览0引用

Amivantamab Plus Chemotherapy with and Without Lazertinib in EGFR-mutant Advanced NSCLC after Disease Progression on Osimertinib: Primary Results from the Phase III MARIPOSA-2 Study

A. Passaro,J. Wang, Y. Wang,S. -H. Lee,B. Melosky,J. -Y. Shih,K. Azuma,O. Juan-Vidal,M. Cobo,E. Felip,N. Girard,A. B. Cortot,R. Califano,F. Cappuzzo,S. Owen,S. Popat,J. -l. Tan, J. Salinas,P. Tomasini,R. D. Gentzler,W. N. William,K. L. Reckamp, T. Takahashi, S. Ganguly,D. M. Kowalski,A. Bearz,M. MacKean, P. Barala,A. B. Bourla, A. Girvin, J. Greger,D. Millington, M. Withelder,J. Xie,T. Sun, S. Shah,B. Diorio,R. E. Knoblauch,J. M. Bauml, R. G. Campelo,B. C. Cho

ANNALS OF ONCOLOGYno. 1 (2024)

引用93浏览0WOS引用

3MO Amivantamab Plus Chemotherapy Vs Chemotherapy in EGFR-mutant Advanced NSCLC after Progression on Osimertinib: A Post-Progression Analysis of MARIPOSA-2

R.D. Gentzler,A. Spira,B. Melosky,S. Owen, T. Burns,E. Massarelli, M. Nagasaka, B. Fang,R.E. Sanborn,O.G. Arrieta Rodriguez, C. Card,F. Cappuzzo,K. Xia, P-L. Chu, S. Shah,B. Diorio, A. Garvin,P. Mahadevia,J.M. Bauml,K. Reckamp

ESMO Open (2024): 102582

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn